CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Income Statement [Abstract]
Net revenues	$ 50,109	$ 21,674	$ 123,365	$ 52,646	$ 82,888
Cost of revenues	15,153	11,118	39,969	28,897	39,870
Impairment of field equipment				6,412	6,412
Gross profit	34,956	10,556	83,396	17,337	36,606
Operating costs and expenses:
Research, development and clinical trials	9,273	10,233	28,055	32,996	41,467
Sales and marketing	16,387	15,865	47,503	43,771	59,449
General and administrative	15,215	12,723	42,660	38,010	51,007
Total operating costs and expenses	40,875	38,821	118,218	114,777	151,923
Operating loss	(5,919)	(28,265)	(34,822)	(97,440)	(115,317)
Financial expenses, net	2,156	2,189	6,785	3,293	6,147
Loss before income tax expense	(8,075)	(30,454)	(41,607)	(100,733)	(121,464)
Income tax expense	3,423	3,174	9,110	8,944	10,381
Net loss	$ (11,498)	$ (33,628)	$ (50,717)	$ (109,677)	$ (131,845)
Basic and diluted net loss per ordinary share	$ (0.13)	$ (0.39)	$ (0.57)	$ (1.29)	$ (1.54)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	89,125,646	85,774,874	88,265,835	85,153,644	85,558,448